SimBioSys Secures FDA Clearance for TumorSight® Risk, Introducing the World's First AI-Powered, MRI-Derived Breast Cancer Recurrence Risk Assessment
<p>Novel software transforms routinely collected MRI, pathology and clinical data into personalized five- and ten-year recurrence risk insight for women with early-stage breast cancer CHICAGO, Oct. 15, 2026 /PRNewswire/ -- SimBioSys®, an AI-driven precision medicine company revolutionizing...</p>
Read original article ↗
Related Articles
The Human Edge in AI: GLG Frontier Powers AI Labs with Critical Expert Judgment
New dedicated practice answers growing demand for trusted, specialized expertise to develop and evaluate models responsi
One of the greatest athletes of all time made consistent recovery a practice that compounded over his career. Now his ap
RWS content solution blending AI and human expertise delivered a 212% modelled 3-year ROI
Independent economic impact study models payback in under six months, with benefits from lower translation costs and fas
While 64% of procurement teams rely on general AI assistants, the largest companies and those with the most comprehensiv